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The incidence and impact of Human Papillomavirus in HIV infected transplant 
patients 
Background   
Human Papillomavirus (HPV) is a common sexually transmitted infection, 
associated with condylomata acuminata, anogenital squamous intraepithelial 
lesions, and ultimately invasive squamous cell carcinoma.  HPV types 16 and 18 
are the most common subtypes in individuals with cervical cancer.  The 
association with these two subtypes in individuals with squamous carcinoma of 
the anus is fundamentally the same as with cervical cancer, and also affects the 
same high risk phenotype.  Human imunnodeficiency virus (HIV) positive 
transplant patients have two modes of immunosuppression – the disease itself 
and the additional immunosuppression required after transplantation, which 
intuitively places them at a higher risk for this type of infection, if compared to 
their HIV negative counterparts. 
Aim   
The first aim is to determine the prevalence of HPV-associated cytological and 
pathological abnormalities of the anus in HIV positive kidney transplant 
recipients and the second aim is to determine if HIV positive solid organ 
recipients carry higher risk for having HPV of the anus than HIV negative solid 
organ recipients. 
Materials and methods  
This is a cross sectional study, conducted at the Transplant unit of Groote Schuur 
Hospital.  14 HIV positive renal transplant recipients and 14 age matched HIV 
negative renal transplant recipients with similar immunosuppression regimens 
and time from transplantation were selected.  Ethical approval for the study was 





consent was obtained from all participants.  Samples for cytology and histology 
were taken from the anal canal.  Demographic data was collected, date of HIV 
diagnosis, duration on anti-retroviral drugs, time since transplant, type of 
immunosuppression, whether there was visible condylomata or not and if there 
were any lesions suspicious of cancer.  Cytology and histology was correlated 
with clinical findings. The statistics were analysed with Stata® software. 
Results   
Mean age was 40.8y ±7.5 (range 27-52) in the HIV positive study group and 41y 
±14.4 (range20-62) in the HIV negative control group. HIV positive patients were 
screened 40.1 months ± 21 (range 13-74.6m) post renal transplant. HIV negative 
patients were screened 55.9 months ± 23.3 (range 8.9-80 m) post renal 
transplant.  Two HIV positive patients had anal warts, compared to 1 in the HIV 
negative group.   No statistically significant difference could be demonstrated 
between the occurrence of intra-epithelial neoplasm on cytology in the HIV 
positive and negative groups.  However, HIV positive patients had a higher 
incidence of HPV on histology that was statistically significant.  There was no 
evidence of squamous intra-epithelial neoplasm found on histology in either 
group. 
Conclusions 
 Evidence of HPV of the anus was demonstrated in both groups, there was no 
demonstrable statistical significance in occurrence between the two groups’ 
cytology.  Histology, however, yielded a significant number of patients with HPV 













Human papillomavirus deoxyribonucleic acid (DNA)  is detected in near 100% of 
anogenital cancers.[1]  60-70% of all HPV infections are eradicated 
spontaneously, but the remainder are at risk of becoming chronic infections, and 
progressing to dysplasia and eventually invasive cancer.  High risk subtypes (HPV 
16 and 18) take longer to eradicate than low risk subtypes.[2 3]  Individuals with 
impaired cellular immunity are at greater risk for HPV infections and anogenital 
cancer. 
 
Human papilloma virus characteristics 
HPV is a small non-enveloped virus, comprised of approximately 8000 base pairs 
of double stranded viral DNA and an icosahedral capsid comprised of proteins E1 
and E2.[4]   
The virus requires access to the basal layers of epithelium by either mechanical 
micro trauma or reduced mucosal barrier function.  The virus is internalised into 
the basal cells, and the viral genome is integrated into the nucleus, mediated by 
the E2 protein.[5]  As the infected cell moves towards the mucosal surface, the 
rest of the viral genome is activated, replicating it’s various components, last of 
which is the E1 and E2 proteins which is required for the complete virus 
assembly, being shed with the top mucosal cell layers.  This process takes 3 
weeks from infection to shedding. [5 6] 
The virus is completely dependent on the host for its DNA replication, which only 
a mitotically active cell is capable of doing.  Both the low and high risk viruses 





apoptosis in cells that are no longer mitotic.[1]  E6 inactivates p53, a tumour 
suppression gene, which leads to failure in apoptosis in cells deficient in the 
retinoblastoma protein (pRb), also a tumour suppressor protein.  E7 acts to 
inactivate pRb, hence the pRb deficient cells.[7]  The action of E6/E7 differs 
between high and low risk HPV subtypes, in that the high risk subtype E6/E7 
expression is able to induce immortality and uncontrolled proliferation in 
keratinocytes, leading to dysplasia and ultimately invasive cancer.[5-7] 
There are over 150 viral types identified to date, of which more than 40 infect 
the human anogenital tract.[8]  They are highly species specific and cannot be 
transmitted interspecies.  [1]  The most common types isolated from anogenital 
warts are 6, 11, 16 and 18.  Subtypes 6 and 11 (low risk subtypes) are most often 
isolated from genital warts and low grade squamous intra-epithelial lesions.  The 
WHO has identified 12 high risk cancer causing HPV subtypes, namely 16, 18, 31, 
35, 39, 45, 51, 52, 56,58 and 59.[5]  HPV 16 and 18 are the most common high 
risk types, 10-20% of cervical cancers have DNA evidence of HPV 18 and 45-65% 
of cervical and anal cancer have DNA evidence of HPV 16, comprising the bulk of 
anogenital cancers. [9] 
 
HPV immunity 
Viral clearance is dependent on the interaction between innate immunity and 
adaptive immunity.  Cell death or injury sets off a cascade of inflammation, 
recruiting local innate immune cells, most importantly dendritic cells, that 
phagocytose the offending antigen, and presents a surface antigen to a T-cell for 
destruction.  Mucosal dendritic cells are called Langerhans cells. 
There are 2 major subsets of T-cells - CD4 which recognises exogenous antigens 
presented on the dendritic cell surface by the major histocompatibility complex 
(MHC) class II, and CD8 which recognises endogenous antigens bound to MHC 





B-cells are produced by bone marrow and stored in the spleen, lymph nodes and 
other immune reservoirs.  They are able to recognise antigens directly without 
help of APC’s.  If a naïve B-cell is activated, plasma cells get activated, releasing a 
large amount of soluble immunoglobulin into the blood stream, these 
immunoglobulins are identical to those expressed by the B-cell.  Immune 
memory develops and a subsequent exposure to the same antigen leads to 
higher affinity and more rapid binding and more effective clearing of the antigen.  
This is the basis for vaccination. [3]    
HPV is dependent on the normal lifecycle of the keratinocyte for replication and 
there is no blood borne phase of the infection.  The keratinocyte is destined for 
death, and the newly assembled virus is propagated to new victims as the cell 
desquamates.  The keratinocyte’s lifecycle is short and the virus has no need to 
destroy the host cell. Because of this, there is no viral induced cell death or 
injury, therefor no inflammation, which means no activation and migration of 
dendritic cells in the mucosal basal layer to infected cells.  Most viruses entering 
into a basal cell should trigger Langerhans activity, by recognition of pathogen-
associated molecular patterns.  The Langerhans cell should then migrate to the 
nearest draining lymph node and present the antigen to a naïve T-cell, which 
should migrate back to the site of infection, and destroy the offending cell.   
Host immunity to HPV had only been studied in animal models and on biopsies of 
regressing warts, and these studies demonstrated high numbers of T-cells (CD4 
and CD8), B-cells and macrophages in the wart stroma.  Failure of activation of 
this mechanism leads to persistent infection, and mounting an immune response 









Sequela of HPV infection 
HPV is a common sexually transmitted infection which is most prevalent in young 
women aged 18-25 years of age.  The lifetime risk of contracting the virus is 70%.  
60-70% of HPV infections (combined high and low risk subtypes) will be 
eradicated spontaneously in a 20 -30 month period, for low risk infections, this 
number is 90%.  High risk (oncogenic) subtype infections appear to be more 
effective at evading host immunity. [2]  It takes 5-6 months to eradicate a low 
risk HPV infection, and 8-14 months to clear a high risk HPV infection.[3] 
Risk factors for contracting the virus are sexual activity related i.e., high number 
of sexual partners, presence of genital warts in partners and lifetime number of 
partners.  Oral contraceptive use is associated not only with higher risk of warts, 
but with increased risk high grade squamous intra-epithelial neoplasm. Impaired 
cellular immunity associated with solid organ transplant and HIV infection result 
in higher rates of anogenital HPV infection.[10]  The use of oral contraception 
and sexual behaviour do not appear to affect eradication of the virus.[2] 
High risk subtypes of HPV can be diagnosed with PCR and are associated with 
squamous-, adeno- and adenosquamous carcinomas of the anogenital tract.   
Almost 100% of cervical cancer is associated with high risk subtypes of the 
HPV.[1 9] Patients that are unable to eradicate the virus (10% of high risk 
infections) are at risk of developing cancer and having persistent infections.    
Cervical cancer is the most common cancer in females in the developing world. 
[1] 
Cervical and anal cancer are biologically similar, they share HPV as an etiologic 
agent, and they both arise in a mucosal transformation zone connecting 








Human immunodeficiency virus (HIV) and HPV 
The HIV related decrease in the CD4 T cell population is partly responsible for 
impaired immunity to HPV.[1 3] 
HIV infection causes reduced numbers of CD4 T cells by two mechanisms: 1) 
infecting activated CD4 T cells cause rapid burst proliferation which leads to cell 
death and 2) supressing the production of naïve CD4 T cells from the thymus by 
either virus induced thymocyte destruction or immunologically supressing 
production.  Suppressing the host’s viral load reverses these effects and result in 
a higher number of circulating CD4 cells.[13] In addition to the effects of 
immunosuppression in a transplanted patient which promotes the persistence of 
HPV infection, co-infection with HIV may directly promote HPV associated 
oncogenesis at the molecular level.  In vitro studies suggest that the HIV-encoded 
tat protein may enhance expression of the HPV E6 and E7 proteins.   
HIV also causes disruption of the basal cell layer integrity via expression of the 
tat and pg120 proteins, which interfere with normal tight junction internalization 
in the basal cell layer of epithelium, leading to decreased integrity and enhanced 
access to basal cells for HPV.[14 15] 
The incidence of HPV infection is 16 times higher in HIV positive patients than in 
HIV negative patients.  The risk for invasive cancer (HPV associated) is 14 times 
greater. [16]  The risk for developing invasive anal cancer in AIDS is 7 times 
higher in women and 38 times higher in men, compared to HIV negative 
patients.[17] 
Multiple HPV type infections are more common in HIV positive patients, 73% 
compared to 23% in HIV negative patients.  Patients with multiple HPV infections 






Regression rates of lesions in HIV negative patients are significantly less than in 
HIV positive patients.  A San Francisco study reports lesion regression in HIV 
positive patients 5-30% compared to 50 to 60% in HIV negative patients.[18] 
Risk factors for developing high grade dysplasia are a high HIV viral load and 
lower CD4 T lymphocyte count.  HIV positive patients with a CD4 count of < 
200/mm
2
 have a threefold increased risk for disease progression and a CD4 
count of >500/mm
2
 confers double the risk compared to HIV negative patients.  
In addition to this, HIV positive patients with high grade dysplasia have been 
shown on histology to have half the amount of Langerhans cells in their anal 
mucosa when compared to HIV negative patients, which significantly increases 
the risk for developing high grade dysplasia. [18 19] 
 
 
Anti-retroviral therapy and HPV 
By the end of 2015, there were 36.7 million people living with HIV in the world. It 
was estimated that 18.2 Million of them were on Highly Active Anti-retroviral 
Therapy (HAART).[20]  The HAART program was rolled out in 1996 in the USA and 
had an enormous positive impact on overall survival in HIV positive individuals by 
decreasing HIV viral load and increasing CD4 lymphocyte numbers.  In South 
Africa HAART was only approved in 2006 and a strategic plan to provide 
treatment to HIV positive patients in South Africa was approved in 2007.[21])  In 
middle to low income countries, life expectancy has increased by about 30 years 
in an individual starting HAART at the age of 20 and another 20 years for those 
starting HAART at 35 years old.  Before 1996, the average life expectancy after 
HIV diagnosis was 10 years.[22]  Since the advent of HAART, the mean age of 
onset of acquired immunodeficiency syndrome (AIDS) has increased, and 2 year 
survival after the onset of AIDS has improved from 49.2% in the pre-HAART era 





definition of AIDS is a CD4 count of less than 200, or any of a list of 20 
opportunistic infections or cancers, including invasive cervical cancer, but not 
anal cancer.[20 23]   
The incidence of invasive anal cancer has risen dramatically with the advent of 
HAART.  Reported incidence of anal cancer in HIV positive males from 1980-1989 
was 10.5 cases per 100 000 person-years, 20.7 cases per 100 000 person-years 
from 1990 to 1995 and 42.3 cases per 100 000 person-years from 1996 to 2004.  
In the period between 1990 and 1995, anti-retroviral drugs had become in use, 
but most often as mono and dual therapies, and were not yet protocol based, as 
with the roll out of HAART in 1996.  Increased screening did not contribute to 
this increase in incidence, as the distribution of stages of anal cancer in both the 
pre-and post HAART era were the same.  [24]  
As previously stated, a low CD4 is associated with decreased disease regression 
and increased progression to invasive cancer.  [17 18] This data is from the 
HAART era.  Contrastingly, before 1996, there was no significant association 
between a low CD4 count and increased risk for developing invasive anal cancer.  
Life expectancy was too short to permit disease progression, and mortality was 
mostly from opportunistic infections.[24]  
 
Immunosuppression in solid organ transplant 
Murray and co-workers performed the first successful renal transplant in 1958, 
made possible because the recipient and donor were monozygotic twins.  The 
graft survived for 11 months.  [25 26] 
For several years after that, survival after transplant was dismal.  In the 50’s, 
recipients received whole body irradiation, but apart from isolated success, 
mortality soon after transplant was common.[27 28]  In France, steroids were 





In the early sixty’s, Azathioprine was synthesized in a laboratory in Boston, and 
Starzl’s work in the sixties, using dual therapy with azathioprine and steroids, 
increased 1 year survival to around 50%. [29 30]. 
In the late 70’s, the first calcineurin inhibitor (CNI), cyclosporine was synthesised, 
[31] added as a third agent in as triple therapy and had increased 1 year survival 
to around 85-95% by the year 2000. [32] 
By the late 80’s another 2 drugs came into use – another CNI namely tacrolimus, 
along with the first mammalian target of rapamycin (mTOR) inhibitor, sirolimus. 
[33] 
The 90’s saw the development of mycofenolate mofetil and mycofenolate 
sodium, as well as the first monoclonal anti-bodies used in transplant, namely 
basiliximab and dacluzimab, both CD25 antagonists. [34] 
There are four classes of transplant immunosuppressive drugs used for 
maintenance. 
1. Anti-proliferatives  
Azathioprine is a prodrug that is converted to 6-mercaptopurine and then 
metabolised to cytotoxic 6-thioguanine nucleotides (6-TGN), which  is 
incorporated into lymphocyte DNA and halts cell replication. 6-TGN is also 
reduced and phosphorylated to deoxy-6-thioguanine triphosphate, which 
binds to the GTPase Rac 1 receptor on lymphocytes.  Blocking of Rac1 
triggers cell cycle arrest via a mismatch repair pathway.  An intermediate 
product in the path from AZA to deoxy-6-thioguanine triphosphate, 
thionosine monophosphate, is converted to s-methylthionosine-
monophosphate, a powerful inhibitor of de novo purine synthesis, 
leading to halt in DNA replication.  The effect of AZA is thus dual – halting 
lymphocyte proliferation and apoptosis of activated lymphocytes.[34 35] 
Mycofenolate mofetil and mycofenolate sodium inhibits purine synthesis 





present on the surface of activated lymphocytes, therefor selectively 
inhibits proliferation of activated lymphocytes.[34] 
2. Calcineurin inhibitors 
Calcineurin inhibitors bind to intracellular proteins (immunophilins) that 
block the effects of clacineurin effectively resulting in a reduction of 
interleukin-2 and reduced T cell proliferation. Tacrolimus is more potent 
than Cyclosporin and binds to a different immunophilin (FK-binding 
protein) to inhibit calcineurin.[34]  
 
3. mTOR inhibitors 
Sirolimus:  inhibition of mTOR results in blockade of T cell activation by 
halting cell cycle progression from the G1 to S phase. [34] 
4. Steroids 
Prednisone and prednisolone:  influence gene transcription resulting in a 
global reduction in cytokines, with a net result of impaired monocyte and 
macrophage function and reduced CD4 lymphocyte numbers.[34] 
 
Thymoglobulin 
The polyclonal antibody, rabbit anti-thymocyte globulin (ATG) is used as 
induction therapy in high risk renal transplant recipients.  ATG is produced by 
introducing human thymocytes to rabbits.  The resulting antibody is polyclonal, 
targeting all cells produced in the thymus.  The thymus comprises 72% T 
lymphocytes, 6% B lymphocytes and the remainder antigen presenting cells and 
stromal cells.  The net effect of ATG administration is rapid T cell depletion, but 






In previous studies it was demonstrated that HIV positive renal transplant 
recipients treated with ATG induction therapy, had a significantly greater decline 
in CD4 count at one year post transplant than those not treated with ATG 
induction therapy, -239 vs. -135. [38] 
All these drugs produce either decreased T-cell function or reduced T-cell 
numbers.  None of them are T-cell specific, and all of them influence B-
lymphocytes to varying degrees as well.  HIV positive transplant recipients will 
therefore have a dual onslaught to their T-cells, HIV and transplant 
immunosuppression.  
HPV eradication requires an intact cellular immune response, most notable, 
normally functioning T lymphocytes.[1 3]  
HPV and anal cancer in solid organ transplant 
In 2003 Adami et al. reported a standardised incidence ratio (SIR) of 10.2 for 
squamous cell carcinoma of the anus, and a SIR of 4 for all cancers  in patients 
from the Swedish Transplant Registry from 1970-1997.[39] 
In 2011, Engels et al reported their study of the US Scientific Registry of 
Transplant Recipients from 1987-2008.  The risk for all cancers were elevated 
two to four fold in solid organ transplant patients, translating into an overall 
incidence of 1375/100 000 person years and a standardised incidence ratio of 
2.1. The highest risks were for cancers with viral aetiologies were anogenital 
cancers (HPV), Hodgkin and non-Hodgkin lymphoma (EBV), Kaposi’s sarcoma 
(HHV8) and liver cancer (Hepatitis B and C).  Anal cancer was nearly 6 times more 
common (SIR 5.7) in these transplant recipients than in the general 
population.[40] 
In 2013, Madeleine et al. echoed Engels’ findings in their publication on the 
incidence of HPV related cancers in solid organ transplant recipients of the US 





In a study by Ogumbiyi et al the overall incidence of HPV infection in solid organ 
transplant recipients was reported as 47%. In the same study it was reported 
that  incidence of anal intra-epithelial neoplasm was 20% in these patients, 
compared to 1% in the patient group presenting for elective anogenital surgery 
[42-45]  Other studies report that invasive anal cancer in transplant recipients is 
6-10 times more common than in the general population. [40 44 46]  The 
incidence rate of in situ anal cancer in solid organ transplant patients is 6.3/100 
000 person years and 11-12/100 000 person years for invasive anal cancer.[40 
41]  
In the US it is estimated that the incidence of cancer 15 years after a solid organ 
transplant is around 15%. Madeleine et al reported 103 cases of invasive anal 
cancer amongst 187649 transplant patients.  It is therefore estimated that 1 in 
2000 of all cancers in transplant patients will be invasive anal cancer.[41 47] 
In a large meta-analysis in 2007, the standardised incidence ratio (SIR) was 
significantly higher for anal cancer in HIV positive patients than for solid organ 
transplant recipients, 28.75 vs. 4.85. [48] It is well known that only 40% of 
transplant recipients with invasive anal cancer have a history of anal warts. [42] 
Patients with HIV have 10 times the risk of cancer (all types) compared to the 
general population, but twice the risk of cancer (all types) when compared to 
solid organ transplant recipients. [49] 
 The use of older immunosuppressive drugs (cyclosporine and azathioprine) 
confers double the incidence of anal cancer compared to newer drugs (MMF and 
tacrolimus).  Cyclosporin A promotes tumourgenesis and growth by inducing 
TGF-β and causing a dose dependent inability to repair DNA.   MMF’s anti-
tumour properties are related to its negative influence on de novo purine 
synthesis.[50] Patients on sirolimus (mTOR inhibitor), showed a significantly 
decreased incidence of invasive cancer.  The use of induction therapy does not 





Screening for HPV 
The anus and the cervix share an embryological origin both develop dysplasia 
and cancer from the human papillomavirus and cytology for both can be 
classified according to the Bethesda system. [51]  
The Bethesda system for reporting endo-cervical smear samples was first 
published in 1988.  Its goal is to improve communication of cervical cytology 
results from the laboratory to the clinician.  [52] 
The 2001 Bethesda system firstly evaluated specimen adequacy, adequate 
cellularity (at least 10 endo-cervical or squamous metaplastic cells) is noted and 
the presence or absence of the squamo-columnar transformation zone is note.  If 
a specimen is inadequate, the reason is noted in the report.[52] 
The reporting system consists of the following categories: 
1. Negative for intra-epithelial lesion or malignancy 
Reporting any non-neoplastic findings is optional 
2. Epithelial cell abnormalities: atypical squamous cells of uncertain 
significance (ASCUS) 
To describe epithelial abnormalities that was too severe to be 
attributed to reactive changes, but was not sufficient to diagnose 
a squamous in situ lesion (SIL).  Pathologists are encouraged to 
mention whether the diagnosis leans more towards reactive 
change or a SIL.  10-20% of women with ASCUS will have an 
underlying high grade dysplasia on repeat cytology. 
 
3. Epithelial cell abnormalities: low grade intra-epithelial lesion (LSIL) 
This category presents a transient HPV infection that will self-
eradicate in 90% of cases in a 20-30 month period.  The HPV 
cytopathic effect cannot be reliably differentiated from cervical 





4. Epithelial abnormalities: High grade intra-epithelial neoplasm (HSIL) 
Subdividing HSIL into CIN II (moderate dysplasia) and CIN III 
(severe dysplasia) is poorly reproducible among pathologists. 
5. Epithelial abnormalities: Atypical glandular cells (AGC) 
Like ASCUS, it is important to note, as 10-39% of patients at follow 
up will have high grade dysplasia. 
Use of the CIN I, II and III system is still widely used and accepted, with the 
understanding that CIN I equals LSIL and CIN II and III represents two degrees of 
HSIL. [52] 
Anal intra-epithelial neoplasm (AIN) shares many similarities with CIN, both are 
diseases of squamous epithelium, both occur at a squamo-columnar epithelial 
junction and both share a causative agent, HPV. 
Because of these similarities between the anus and cervix, the Bethesda system 
is widely used to report anal cytology. 
Anal cytology has 60-90% sensitivity for AIN, but only modest ability to 
distinguish between grades of AIN. [46] In 2007 Cranston demonstrated that any 
dysplasia on anal cytology has a 96% positive predictive value (PPV) for any grade 
of anal dysplasia, but a poor PPV (56%) for predicting the exact grade of 
dysplasia. [51]  Palefsky compared anal cytology to anal biopsies in HIV positive 
and HIV negative patients, and showed 69% sensitivity in the HIV patients and 
47% sensitivity in the HIV negative group.  Sensitivity in the HIV positive group 
was comparable to that of cervical cytology sensitivity.  [53] 
De Ruiter showed a similar trend in 1994 – that anal cytology has good sensitivity 
(87.5%), but poor specificity (16.3%), a positive predictive value of 37.4 and a 
negative predictive value of 69.6%.[54] 
The conclusion of these 3 studies is that positive anal cytology has to be followed 






Palefsky et al. performed anal biopsies after staining the anus with acetic acid via 
an anoscope.   Acetic acid stains abnormal keratinised epithelium at the 
squamocolumnar junction in the anus.  These areas were targeted to biopsy.[53] 
Biopsy specimens are assessed for AIN on standard haematoxylin and eosin stain.  
In low grade dysplasia (AIN I and II) the proliferation zone above the basement 
membrane becomes thicker, and there is a decreased amount of mature 
keratinocytes.  High grade dysplasia is characterised by full thickness 
proliferation and marked angioneogenesis.  Once the basement membrane is 
























This cohort study was conducted from September 2014 to November 2014.  A 
total of 27 patients were enrolled in this study.  14 HIV positive renal transplant 
recipients, aged between 27 and 52 years old, 50% male and 50% female, that 
received a renal transplant (first episode) between 2008 and 2013 at the Groote 
Schuur Transplant Unit were contacted and screening  for anal human 
papillomavirus offered to them.   One of the patients that consented, did not 
attend the scheduled screening, and was therefore excluded from this study.  All 
of the HIV positive renal transplant recipients were known to be HIV positive at 
the time of transplant and all them had received kidneys from HIV positive 
donors. 
  A similar group of 14 HIV negative renal transplant recipients were selected 
from the transplant record at Groote Schuur, aged between 20 and 62, 57% 
female and 43% male, that received a renal transplant (first episode) between 
2007 and 2013.  These patients were selected to match the age, gender and time 
of transplant of the HIV group, to negate any effect these 3 variables might have 
on results.  The same screening offered to the HIV group, was offered to them.   
Written informed consent was obtained from all participants by the principle 
investigator, and the study was approved by the University of Cape Town Faculty 










Data collected for each patient was gender, age, months since transplant, HIV 
status, type and duration of ARV’s and type of transplant immunosuppression.  
Appearance of the anus before and after acetic acid staining was documented.  
This date was collected on an excel spread sheet.  Descriptive data was 
categorised into numbers, to facilitate the data processing.    
 
Anal cytology 
The sampling was conducted at the Obstetrics and Gynaecology outpatient 
Department at Groote Schuur Hospital.  Before sampling was started, an external 
examination of the anus and perineum was performed and noted if there were 
any macroscopic lesions present.   
Patients were asked to assume the lithotomy position, a nylon cervical cytology 
brush, moistened with 0.9% saline was inserted into the anal canal and rotated in 
either direction.  The contents were then transferred onto 4 glass slides and fixed 
using an aerosol cytological fixative, and dispatched for cytological examination.   
 
Anal histololgy 
Subsequently, a gauze swab was soaked in 5% acetic acid and inserted with a 
forceps into the anal canal and left in place for two minutes.  The anus was then 
examined for any white areas that may indicate dysplastic epithelium.  If such 
areas were identified, the area was injected with a 1% lignocaine local 
anaesthetic agent, and biopsied.  Samples were fixed in 10% formalin and sent 






Cytological and histological examinations were done by two different 
pathologists, blind to each other’s results and blind to the HIV status of the 
patients. 
Cytology was reported as per the Bethesda criteria for cervical cytology, and was 
then categorised as either normal, LSIL or HSIL.[52]  A smear was deemed 
adequate if columnar epithelium was present on the slide.  Smears that did not 
contain columnar epithelium were repeated at the next outpatient visit.  All 
smears in this study were adequate. 
Histological examination was performed with standard haematoxylin and eosin 
staining, and examined for koilocytes, which are cells that have undergone 
morphological changes associated with HPV infection, namely peri-nuclear 
vacuolation (or halo), irregularity of the nuclear membrane contour, nuclear 
hyperchromasia and nuclear enlargement.  The samples were then examined for 
any sign of dysplasia. 
 
Statistical analysis 
Demographic data, HIV status, time from transplant, time on ART, macroscopic 
appearance of the anus, cytology results and histology results were tabulated in 
Excell format.  All descriptive data was categorised numerically to facilitate 
statistical calculations, and the statistics were determined using the Stata 
program. 
Cytology was classified as 1) normal, 2) LSIL, 3) HSIL and 4) evidence of invasive 
cancer. 
Histology was classified as 1) normal and 2) HPV, because there was no dysplasia 







A total of 27 renal transplant recipients were examined and biopsied.  13 (48%) 
were HIV positive and 14 (52%) were HIV negative.  The mean age in the HIV 
negative group was 40.8 years ±7.5 (range 20-62) and 41 years ± 14.4(range 27-
52) in the HIV positive group.  All study participants had only one renal transplant 
episode.  There was no statistically significant difference in age between the two 
groups (p=0.89). 
Mean time from transplant in the HIV positive group was 40.1 months ±21 (range 
13-74.6) and 55.86 months ±23.3 (8.9-84) in the HIV negative group.  There was 
no statistically significant difference in months since transplant between the two 
groups (p=0.08). 
  n (percentage) Mean age (range) Mean months since transplant 
(range) 
HIV +  13 (48.15%) 40.85 (27-52) 40.08 (12.99-74.6) 
HIV -  14 (51.85%) 41.43 (20 – 62) 55.86 (8.98 – 84.03) 
Table 1  
 
All the patients in the HIV positive cohort were on the same immunosuppression 
regime, namely Tacrolimus, MMF and prednisone.  The majority (n=7, 50%) of 
the HIV negative cohort was also on this regime.  Of the remainder of the HIV 
negative cohort, 3 were on Tacrolimus, Azathioprine and prednisone,  2 were on 
Sirolimus, MMF and prednisone, one was on Cyclosporin, MMF and prednisone, 












Immunosuppressive drugs were assigned into 5 numerical categories, 
representing all the drug combinations used in both cohorts: 
1. Tacrolimus, MMF and prednisone 
2. Tacrolimus, Azathioprine and prednisone 
3. Sirolimus, MMF and prednisone 
4. Sirolimus, Azathioprine and prednisone 
5. Cyclosporine, MMF and prednisone 
 
 
See Table 2 for distribution of immunosuppression amongst patients. 
 








13 (100%) 7 (50%) 20 (74%) 
Immunosuppression 
2 
0 3 (21.43%) 3 (11.11%) 
Immunosuppression 
3 
0 2 (14.29%) 2 (7.41%) 
Immunosuppression 
4 
0 1 (7.14%) 1 (3%) 
Immunosuppression 
5 
0 1 (7.14%) 1(3%) 
Total 13 14 27 











The mean time since HIV diagnosis in the HIV+ cohort was 8.92  (range 3-16) 
years, and the mean time since initiation of HAART was 7.15 (range 3-14 years) 
 
 Time since HIV diagnosis in years 
(range) 
Time on HAART in years 
(range) 
HIV + males 9.8 (3-16)  7.3 (3-14) 
HIV + 
females 





Anti-retroviral drugs regimes were varied amongst the HIV + cohort, as 
demonstrated in table 4.  23% of patients were on the combination of 





























2 3 0 1 0 1 0 0 7 
HIV + 
females 
0 0 1 1 2 0 1 1 6 
















 n warts n LSIL n HSIL n Normal 
cytology 
n HPV on 
histo  
 
HIV + Male 
1 3 2 2 1 
HIV + Female 1 2 1 3 3 








5 (38.46%) 4 (30.77%) 
HIV - male 1 1 1 4 0 
HIV - Female 0 3 1 4 0 
Subtotal HIV – 
(%HIV-) 




8 (57.14%) 0 






13 (48.15%) 4 (14.81%) 
Table 5 
 
Table 5 outlines the numbers of disease per cohort as per clinical, cytological and 
histological evaluation. 
A total of 14 (51.8%) patients had abnormal cytological findings, 8 (61.5%) in the 
HIV positive cohort, and 6 (42.9%) HIV negative cohort, Fisher’s exact test shows 
no significant difference (p = 0.806).  On cytology, the most common result was a 
normal smear (n=13, 48.15%), followed by LSIL (n=9, 33.33%) and HSIL (n=5, 
18.52%).  There was no significant difference in this distribution between the two 
groups.   
61.5% (n=8) of all the HIV patients had cytological evidence of HPV, compared to 
42.9% (n=6) the HIV negative group. 
 HPV was proven histologically in 4 (30.77%) of the 13 HIV positive patients, and 
in none of the HIV negative patients.  HPV positive histology in the HIV + cohort 
was significantly more common, p=0.014.  There was no evidence of dysplasia in 
any of the histology specimens. 
Two (15.38%) of the HIV positive group had anal warts and one (7.14%) of the 






 HIV - with 
HPV on 
Histology 
 HIV - with 
no HPV on 
histology 
HIV + with 
HPV on 
Histology 
HIV + with 





0 8 1 4 9 
LSIL 0 4 1 4 9 
HSIL 0 2 2 1 5 




Table 6 demonstrates the relationship between histology and cytology findings.  
To calculate sensitivity, specificity, positive predictive value (PPV) and negative 
predictive value, cytology was grouped into normal and abnormal (combined LSIL 
and HSIL). 
The sensitivity of anal cytology for detecting histologically proven HPV in the HIV 
positive group was 75%.  Sensitivity for the HIV negative group could not be 
determined, due to no positive histology in the HIV negative group.  Specificity in 
the HIV + group was 44.44% and 52.17% in both cohorts combined.  The PPV of 
anal cytology was 37.5% in the HIV + group and 21.42% overall.  The NPV of anal 
cytology for having HPV of the anus in the HIV+ group was 80% and 92% overall. 
The relative risk for an HIV positive patient with abnormal anal cytology to have 
HPV on histology was 1.9 (95% CI 0.26 – 13.42, p=0.53), and 2.78 (95%CI 0.26-









Table 7 examines the relationship between warts and cytology results.  It 
indicates that having warts, have a PPV of 66.66% for having positive cytology, 
and that only 50% of patients that don’t have warts, will actually have negative 
cytology too.  The relative risk when combining both cohorts for having positive 
cytology if a patient has warts is 1.3 (95% CI 0.54 – 3.26, p= 0.53), and 1.8 (95% CI 
1.07 – 3.14, p= 0.027) in an HIV positive patient.  The relative risk could not be 
calculated for the HIV negative group alone, because the patient with warts had 
normal cytology. 
 
 HIV + positive 
cytology 
HIV + negative 
cytology 




Warts 2 0 0 1 
No warts 6 5 6 7 
Table 7 
 
Table 8 examines the relationship between warts and histology outcomes.   If a 
patient from any of the two cohorts did not have warts, they had an 83.8% 
probability of having negative histology too.  None of the HIV positive patients 
with warts had positive histology, therefor the positive predictive value and 
relative risk to have abnormal histology if a patient had warts, could not be 
determined.  
 
 HIV +  
Positive histology 
HIV +  
negative histology 
HIV –  
positive histology 
HIV – 
 negative histology 
Warts 0 2 0 1 








Table 9 examines the relationship between the acetic acid stain findings and the 
cytology outcomes.  HIV positive patients with a positive stain had an apparently 
increased relative risk of 1.2 (95% CI 0.16 – 9.02, p=0.85) of having positive 




HIV +  
positive 
cytology 
HIV +  
negative 
cytology 






No white stain 0 0 3 2 
Single white stain 6 4 1 1 
Multiple white stains 2 1 0 1 
Circumferential white 
stains 
0 0 2 4 
All stains 8 5 3 6 

















Table 10 examines the relationship between acetic acid stain findings and 
histology outcomes.  Of 27 patients screened, 5 (18.52%) had no anal areas of 
white staining with acetic acid.  The most common finding was a single white 
stain in 12 patients (44.44%).  The sensitivity of any positive acetic white stain for 
finding HPV on histology in the HIV positive cohort was 100% in this study.  The 
specificity was 30.77%.  The positive predictive value of a stain for having 
positive histology was only 30.77%, but the negative predictive value of no stain 
for having had normal histology was 100%.   
 
 HIV + positive 
histology 
HIV + negative 
histology 
HIV – positive 
histology 
HIV – negative 
histology 
No white stain 0 0 0 5 
Single white stain 4 6 0 2 
Multiple white 
stains 
0 3 0 3 
Circumferential 
white stains 
0 0 0 6 
All stains 4 9 0 11 
Table 10  
 
In both groups there was no association between time on immunosuppression 













There are no studies comparing the incidence of HPV of an HIV positive solid 
organ transplant cohort to that of an HIV negative solid organ transplant cohort.  
There is also currently no screening program for HPV in solid organ transplant 
recipients in South Africa. 
In this cohort study, cytological evidence of HPV was more common in the HIV 
cohort (n=8, 61.5%) than in the HIV negative cohort (n=6, 42.9%) It may indicate 
that more HIV positive patients have HPV at the time of transplant than HIV 
negative patients, or that HIV positive patients are more likely to acquire new 
infections post-transplant than HIV negative patients.    
HPV proven on histology was significantly more common in the HIV + cohort (4 vs 
0).  The risk for an HIV positive patient to have HPV is 16 times higher than that 
of a HIV negative patient [16].   Screening at time of transplant is likely even 
more important in HIV positive solid organ recipients.  
The numbers of patients affected by HPV of the anus compares to those found in 
other studies, it highlights the need for screening in these patients after 
transplant.  [12 42]   
We did not know the HPV status of our patients at time of transplant, HPV is not 
routinely tested for in South Africa prior to transplant.  The fact that that there 
was no significant association between disease severity on cytology and time 
from transplant, is reassuring.  However, knowing whether the infections we 
encountered were acquired pre- or post-transplant, could offer more accurate 
insight into the natural history of the disease in transplant patients.   Valuable 
information about new infections (post-transplant) and which patients are more 
likely to acquire new infections could be learnt. 
The sensitivity of anal cytology for detecting HPV proven on histology could only 
be tested In the HIV positive group, as there was no HPV positive histology in the 





other published results.   Also in keeping with other publications, the specificity 
of anal cytology was low, 44.4% for the HIV + group and 52.17% for both cohorts 
combined.   Our positive predictive value was also low (37.5%), but with a higher 
negative predictive value, as in other studies.   We will therefor also recommend 
that cytology always be followed up with biopsy.  [46 53 54]   Patients with no 
abnormal acetic acid staining, could potentially be followed up without initial 
biopsy. 
The absence of warts was not a reliable indicator of disease, as was discussed by 
Kwak et al. in 2009. 
Limitations of the study are a small sample size, with a correspondingly small 
control group, given the limited amount of HIV positive transplant patients.  
Histology may not be representative, the patients in this cohort generally did not 
tolerate anal biopsy under local anaesthetic very well, most found it 
uncomfortable, and biopsies were generally difficult.  This is in contradiction with 
other studies describing anal biopsies. It may be that histology done under 
sedation, spinal or general anaesthetic will yield better results.[53] 
Another limitation of the study is the heterogeneity of immunosuppression in 
the HIV negative group. Matching the cohorts for age, time from transplant and 




It is encouraging that none of our patients have invasive cancer at this stage, but 
this study highlights the importance of early identification of HPV infections.  
Given the increased likelihood of disease progression in both groups, we propose 
HPV screening at the time of transplant and yearly follow up with acetic acid 
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APPENDIX 1: Consent form 
 



























Study Conducted by: 
Dr. Janie Botha, Principal Investigator (PI), Prof. Elmi Muller,  Prof Helen 




Collection of anal and cervical Pap smear for Storage and Testing 
 
A. Who is conducting this sub-study? 
Dr. Elmi Muller, Principal Investigator (PI), Dr. Janie Botha, Dr. Claire 
Warden and Dr. Genevieve Learmonth are conducting a research study. 
   
B. Why am I invited to participate in this optional sub-study? 
You are being asked to take part in this study because you had a 
transplant in the last 5 years.  The data obtained from this study will be 
compared to data from a group of patients who are enrolled as a 
participant in “Renal Transplantation in HIV positive patients: Using HIV 
positive cadaver donors for HIV positive recipients.”  
 
Research studies include only people who choose to take part.  Please 
take your time to make your decision and discuss it with your friends, 
family and/or physician. Remember that your participation is completely 
voluntary. 
 
C. What is the purpose of this optional sub-study? 
Patients who are immunosuppressed for any reason (after receiving a 
transplant) are thought to be at a higher risk for the development of HPV 
(a virus)-associated cancer in the cervix as well as in the anus. The 
purpose of the Pap smear(s) of the anus is to look for HPV itself. The pap 
smear of the anus also allows for early detection of any pre-cancerous 






The study investigators would like to learn more about anal HPV infection 
and the course of anal disease over time.  Because HPV infection of the 
anus can be seen in both men and women, if you are sexually active, you 
will be asked to have an anal examination and a Pap smear of the anus to 
collect cells to test for anal HPV infection. 
 
If a potentially pre-cancerous area is found, your primary medical care 
provider and the study doctors will discuss the results so that 
arrangements for appropriate follow-up can be made. If treatment is 
required, referrals will be made outside of the study.   
 
You may choose not to participate in the studies of the anal region or you 
may stop participating in them at any time. Your decision will not affect you 
follow-uo transplant study.  You may agree or refuse to participate in these 
HPV studies by checking the correct choice at the end of this consent 
form. 
 
D. Are there potential conflicts of interest? 
Groote Schuur Hospital investigators must satisfy legal requirements for 
identifying and managing potential conflicts of interest before a research 
study can be approved.  The purpose of these requirements is to ensure 
that the design, conduct and reporting of the research will not be biased by 
any conflicting interests.  If at any time you have specific questions about 
the financial arrangements or other potential conflicts for this sub-study, 
please feel free to contact any of the individuals listed in Section M. 
 
The investigators of this research do not have any financial interest in the 
sponsor or in the study; this means that the investigator will not be 
financially affected by the results of the study (positive or negative).  
 
The person inviting you to participate in this research may also be your treating doctor.  In such cases, the 
doctor has an interest in both your care and promoting the successful conduct of this research.  Sometimes 
these two interests may cause conflict.  You can choose not to participate in the research and still receive 
treatment from your doctor.  If you wish, you may also request to speak to another doctor who is not a member 
of the research team about your options. 
 





In the first year of the study, about 25 people who had transplants in the 
last 5 years will be invited to take part in study. 
 
F. What will I be asked to do? 
For the anal Pap smear, you will have a swab inserted into the anal canal 
to collect cells and to look for HPV.  If this is abnormal, you will be referred 
to a specialist for the following exams and tests: 
 
You will have a visual examination of the anal region.  An instrument 
called an anoscope will be inserted into the anal canal.  The anoscope 
allows the specialist to look at the inside of the anal canal.  Three percent 
acetic acid (diluted vinegar) will be applied to the surface of the anal canal 
as well as to the inside of the canal.  During the anoscopy, if any areas of 
abnormality are seen, a biopsy (removal of a small piece of anal skin) may 
be required.  To perform this biopsy, the anal skin will be numbed by 
injecting a numbing medicine (similar to that used by a dentist) with a 
small needle.  After the skin becomes numb, a very small piece of anal 
skin will be removed.  This biopsy skin will be sent to the Department of 
Pathology, at the University of Cape Town, for examination.  If the area of 
abnormality is large enough, a second piece of anal skin may be needed 
for analysis.  These procedures take about 30 minutes. 
 
G. Are there any risks and discomforts? 
Insertion of an anal swab, an anoscope and application of acetic acid may 
cause some discomfort. Anal biopsy may be associated with discomfort 
from the needle stick for anesthesia, bleeding, temporary discomfort after 
the anesthetic wears off and rarely, infection or allergic reaction to the 
anesthesia.   
 
H. What other options are there? 
You may choose to not participate the study.  If you choose to not 
participate in this study, neither your medical care nor your ongoing 
participation in the main study will be affected by your decision. 
 






The research team will share information among themselves as part of the 
research study process.  In addition, various institutional committees and 
governmental agencies that oversee research may request or require 
access to your identifiable health information.  These include the Research 
Ethics Committee of Groote Schuur Hospital.  
 
Why would my health information be shared as part of the sub-
study? 
 
Research involves the gathering and analysis of information.  With medical 
research, the research team is gathering and analyzing health information 
about individuals in the hope that they will be able to answer specific 
questions about a bodily function, disease, or wellness.  Those team 
members who act in a supportive role to the research study use health 
information when necessary for various administrative tasks, such as 
tracking data, making reports that are required by government oversight 
agencies or the study sponsor, and assisting the researchers with other 
data-related tasks.  The Institutional Review Boards / Research Ethics 
Committees act as watchdog groups for the protection of the rights and 
interests of research subjects.   
 
It is important for you to know that if your health information is used for 
teaching purposes outside the study, or to prepare a medical journal report 
about the research study, your identifiable health information will not be 
made public; your identity will be kept confidential in those circumstances.    
Each time your identifiable health information is disclosed to any of the 
individuals listed above, precautions will be taken to minimize the 
possibility that the information shared could directly identify you.  When 
possible, all identifying information will be coded.  This means that the 
researchers will assign a unique code to represent your identifiable data 
so that people who see the coded data will not be able to identify you.    
 
You may authorize the research team to share your identifiable health 
information in connection with the research study.  Whenever we disclose 
any of your identifiable health information based on your authorization, 
your written statement will accompany the information. 
 





You will not be paid for your participation in this study. 
 
K. What happens if I need emergency care? 
In the event of injury or illness resulting from this study, you should 
immediately contact one of the personnel listed in Section M “Whom do I 
call if I have questions or problems?”   
 
L. What are my rights as a human research participant? 
Taking part in this sub-study is voluntary.  You may choose not to take part or 
may leave the study at any time.  Your decision not to participate or to withdraw 
from the study means that you will not or will no longer undergo any research-
related procedures.  You will, however, still be able to receive treatment and 
services at Groote Schuur Hospital that are not related to this research.   If you 
leave the study: 
• We will no longer be able to allow you to participate in the research 
sub-study; and  
• We will stop collecting any additional identifiable health information 
about you.  However, we are allowed by law to continue to use the 
health information we already have about you, as necessary to 
maintain the integrity of the research study and make reports that 
oversight agencies require of us. 
• You also have the right to revoke or withdraw your authorization for us 
to use your identifiable health information.  If you wish to revoke or 
withdraw your authorization, you must do so in writing, and provide that 
written revocation to the investigator Elmi Muller, MD, whose mailing 
address is: Renal Unit, Groote Schuur Hospital, Observatory, Cape 
Town 7925.  
 
During your participation in this sub-study, we will tell you about any new 
information that may affect your health, welfare, or willingness to stay in 
this study. 
 
M. Whom do I call if I have questions or problems? 
For questions about the study or a research-related injury, please contact 
the numbers below 24 hours daily: 
Groote Schuur Transplant Unit 021 404 3327 
Groote Schuur Renal Clinic 021 404 3311 






For questions about your rights as a research participant, contact the 
Groote Schuur Hospital Research Ethics Committee (REC) office at E52 
24 Old Main Building, Groote Schuur Hospital, Observatory (Tel: 021 406 
6492/ 406 6626/ 4066338).  The REC is a group of people who review the 
research to protect your rights and welfare. 
 
N. Consent and Authorization Provisions   
Your signature below means that:  (1) you have carefully read and 
understood the information presented in this informed consent form; 
(2) the information concerning the research study and its involved 
procedures has been fully explained to you and your questions have 
been answered to your satisfaction; (3) you have received all of the 
information you desire; (4) you consent to your participation in the 
research sub-study, and (5) you authorize the use and disclosure of your 
identifiable health information as described in this form.  If you have any 
additional questions during the course of your involvement in the 
research, you should contact the investigator(s), the REC Chair(s) and/or 
the REC Office at any time. 
 
Your signature below reflects that, after considering both the potential 
risks, anticipated benefits and alternatives (and their relative risks and 
benefits) of participation, you voluntarily agree to participate in this 
research and authorize the research team to create, obtain, use or 
disclose your identifiable health information as described in Section L of 
this document, and in connection with this research study. By consenting 
to participate in the research, you are not giving up any of your legal 












O. What if something goes wrong? 
 
The University of Cape Town (UCT) undertakes that in the event of you suffering any 
significant deterioration in health or well-being, or from any unexpected sensitivity or 
toxicity, that is caused by your participation in the study, it will provide immediate 
medical care. UCT has appropriate insurance cover to provide prompt payment of 
compensation for any trial-related injury according to the guidelines outlined by the 
Association of the British Pharmaceutical Industry, ABPI 1991. Broadly-speaking, the 
ABPI guidelines recommend that the insured company (UCT), without legal 
commitment, should compensate you without you having to prove that UCT is at fault. 
An injury is considered trial-related if, and to the extent that, it is caused by study 
activities. You must notify the study doctor immediately of any side effects and/or 
injuries during the trial, whether they are research-related or other related 
complications. 
UCT reserves the right not to provide compensation if, and to the extent that, your 
injury came about because you chose not to follow the instructions that you were given 
while you were taking part in the study. Your right in law to claim compensation for 
injury where you prove negligence is not affected. Copies of these guidelines are 
available on request. 
 
 




      
Name of Patient Signature of Patient Date 
of Signature 
 
SIGNATURE BY THE INVESTIGATOR: 
I attest that all the elements of informed consent described in this form 
have been discussed fully in non-technical terms with the subject.  I 
further attest that all questions asked by the subject were answered to 
the best of my knowledge.  The subject has been provided with the 






    
Signature of the Investigator Who Obtained Consent Date 
of Signature 
 
SIGNATURE BY THE WITNESS/TRANSLATOR  
(Signature of a witness is only required when a non-English speaking 
subject is consented with the assistance of a translator.  The signature of 
the witness below attests that the translator has presented the elements 
of consent to the subject, orally and in his/her preferred language, and 
that a summary of the oral presentation, in a language the subject can 
understand, has been given to the participant.) 
 
 
    

















Appendix 2: Data analysis 
___ ____  ____ ____ ____ (R)     
 
/__ / ____/ / ____/     
 
___/ / /___/ /   /___/   11.2 Copyright 1985-2009 StataCorp LP 
 
Statistics/Data Analysis StataCorp    
 
     4905 Lakeway Drive 
 
     College Station, Texas 77845 USA 
 
     800-STATA-PC  http://www.stata.com 
 
     
979-696-4600 
    
      stata@stata.com 
 
     979-696-4601 (fax) 
 
 
Single-user Stata perpetual license: 
 
Serial number:  30110550580  





1. 10.00 MB allocated to data  
 
. use "/Users/Kathryn/Desktop/Stats 2014/Janie Engelbrecht/database v1.dta" 
 
. do "/var/folders/8y/ry3l_v0s65lfzy7mmcm7xnwm0000gn/T//SD02002.000000" 
 




. tab hiv_status 
 
HIV status  Freq. Percent Cum.
 
     
 
Negative  14 51.85 51.85
 
Positive  13 48.15 100.00
 
     
 
Total  27 100.00  
 








     
 
Female  14 51.85 51.85
 
Male  13 48.15 100.00
 
     
 
Total  27 100.00  
 
 




    --------------  --------------  
 




age 27 41.15 11.39 20.00 34.00 40.00 52.00 62.00
------------------------------------------------------------------------------- 
 




    --------------  --------------  
 



















   
 
    
 
disease      
 
before      
 
stain   Freq. Percent Cum.
 
      
 
None  21 77.78 77.78
 
Warts   3 11.11 88.89
 
Other   3 11.11 100.00
 
      
 
Total  27 100.00  
 
 








     
 
No white areas  5 18.52 18.52
 
Small white area  12 44.44 62.96
 
Multiple white areas  4 14.81 77.78
 
Circum white  6 22.22 100.00
 
     
 
Total  27 100.00  
 
 





   
 
    
 
essives   Freq. Percent Cum.
 
      
 
T-M-P  20 74.07 74.07
 
T-A-P   3 11.11 85.19
 
S-M-P   2 7.41 92.59
 
S-A-P   1 3.70 96.30
 
C-M-P   1 3.70 100.00
 
      
 
Total  27 100.00  
 








      
 
Lam-Sta-Eff  1 7.69 7.69
 
Lam-Efa-Sta   4 30.77 38.46
 
Lam-Sta-Nev   1 7.69 46.15
 
Lam-Efa-Aba   2 15.38 61.54
 
Ten-Lam-L/R   2 15.38 76.92
 
Ten-Lam-Efa   1 7.69 84.62
 
L/R-Emt/Ten   1 7.69 92.31
 
Aba-Lam-Efa   1 7.69 100.00
 
      
 
Total  13 100.00  
 
. tab hivdx_date    
 
Year of Dx 
 
 
   
 
    
 
of HIV   Freq. Percent Cum.
 












1999   1 7.69 15.38
 
2002   2 15.38 30.77
 
2005   1 7.69 38.46
 
2006   4 30.77 69.23
 
2008   2 15.38 84.62
 
2009   1 7.69 92.31
 
2011   1 7.69 100.00
 
      
 
Total  13 100.00  
 








      
 
1  13 48.15 48.15
 
2   9 33.33 81.48
 
3   4 14.81 96.30
 
4   1 3.70 100.00
 
      
 
Total  27 100.00  
 








      
 
1  23 85.19 85.19
 
2   4 14.81 100.00
 
      
 





. **Differences between hiv status groups  
.  
.  









 HIV status  
Gender Negative Positive Total
    
Female 8 6 14
 57.14 42.86 100.00
 57.14 46.15 51.85
    
Male 6 7 13
 46.15 53.85 100.00
 42.86 53.85 48.15
    





 51.85 48.15 100.00







. univar age, by (hiv_status) 
 




    --------------  --------------  
 




age 14 41.43 14.38 20.00 32.00 38.00 53.00 62.00
------------------------------------------------------------------------------- 
 




    --------------  --------------  
 




age 13 40.85 7.53 27.00 35.00 42.00 46.00 52.00
------------------------------------------------------------------------------- 
 
. **age normally distributed 
 
. ttest age, by(hiv_status) 
 
Two-sample t test with equal variances 
 
Group Obs Mean Std. Err. Std. Dev. [95% Conf. Interval]
       
Negative 14 41.42857 3.844097 14.38329 33.12391 49.73324
Positive 13 40.84615 2.087343 7.526023 36.29822 45.39408
       
combined 27 41.14815 2.191478 11.38725 36.6435 45.6528
       
diff  .5824176 4.471307  -8.626411 9.791247
       
 
diff = mean(Negative) - mean(Positive)  t = 0.1303
Ho: diff = 0  degrees of freedom = 25
Ha: diff < 0 Ha: diff != 0  Ha: diff > 0 
Pr(T < t) = 0.5513 Pr(|T| > |t|) = 0.8974 Pr(T > t) =0.4487
 
. univar tx_months, by (hiv_status) 
 




    --------------  --------------  
 




tx_months 14 55.86 23.24 8.98 36.39 62.50 73.02 84.03
------------------------------------------------------------------------------- 
 




    --------------  --------------  
 




tx_months 13 40.08 21.79 12.99 21.53 37.97 56.19 74.60  
------------------------------------------------------------------------------- 
 
. **tx_months normally distributed 
 












Group Obs Mean Std. Err. Std. Dev. [95% Conf. Interval]
       
Negative 14 55.85988 6.210602 23.23794 42.44269 69.27707
Positive 13 40.07924 6.042211 21.7855 26.91439 53.24409
       
combined 27 48.2618 4.528158 23.529 38.95403 57.56956
       
diff  15.78064 8.686401  -2.109337 33.67062
       
 
diff = mean(Negative) - mean(Positive)  t = 1.8167
Ho: diff = 0  degrees of freedom = 25
Ha: diff < 0 Ha: diff != 0  Ha: diff > 0 
Pr(T < t) = 0.9594 Pr(|T| > |t|) = 0.0813 Pr(T > t) =0.0406
 









Macroscopi    
c disease    
before HIV status  
stain Negative Positive Total
    
None 12 9 21
 57.14 42.86 100.00
 85.71 69.23 77.78
    
Warts 1 2 3
 33.33 66.67 100.00
 7.14 15.38 11.11
    
Other 1 2 3
 33.33 66.67 100.00
 7.14 15.38 11.11
    
Total 14 13 27
 51.85 48.15 100.00
 100.00 100.00 100.00
 
 
. tab prestain hiv_status, exact 
 
Enumerating sample-space combinations: 
stage 3: enumerations = 1 
stage 2: enumerations = 2 







c disease  





stain Negative Positive Total 
      
None 12 9 21 
Warts 1 2 3 
Other 1 2 3 
      
Total 14 13 27 
 Fisher's exact = 0.525
 









 HIV status  
Post stain Negative Positive Total
    
No white areas 5 0 5
 100.00 0.00 100.00
 35.71 0.00 18.52
    
Small white area 2 10 12
 16.67 83.33 100.00
 14.29 76.92 44.44
    
Multiple white areas 1 3 4
 25.00 75.00 100.00
 7.14 23.08 14.81
    
Circum white 6 0 6
 100.00 0.00 100.00
 42.86 0.00 22.22
    
Total 14 13 27
 51.85 48.15 100.00
 100.00 100.00 100.00
 
 
. tab poststain hiv_status, exact 
 
Enumerating sample-space combinations: 
stage 4: enumerations = 1 
stage 3: enumerations = 5 
stage 2: enumerations = 16 
stage 1: enumerations = 0 
 
 HIV status  
Post stain Negative Positive Total
    





Small white area 2 10 12





Circum white  6 0 6
      
Total  14 13 27
Fisher's exact =   0.000 
 









Immunosupp HIV status  
ressives Negative Positive Total
    
T-M-P 7 13 20
 35.00 65.00 100.00
 50.00 100.00 74.07
    
T-A-P 3 0 3
 100.00 0.00 100.00
 21.43 0.00 11.11
    
S-M-P 2 0 2
 100.00 0.00 100.00
 14.29 0.00 7.41
    
S-A-P 1 0 1
 100.00 0.00 100.00
 7.14 0.00 3.70
    
C-M-P 1 0 1
 100.00 0.00 100.00
 7.14 0.00 3.70
    
Total 14 13 27
 51.85 48.15 100.00
 100.00 100.00 100.00
 
 
. tab immunosup hiv_status, exact 
 
Enumerating sample-space combinations: 
stage 5: enumerations = 1 
stage 4: enumerations = 2 
stage 3: enumerations = 2 
stage 2: enumerations = 2 
stage 1: enumerations = 0 
 
Immunosupp HIV status  
ressives Negative Positive Total





T-M-P 7 13 20





S-M-P  2 0 2 
S-A-P  1 0 1 
C-M-P  1 0 1 
      
Total  14 13 27 
 Fisher's exact =  0.014
 









 HIV status 
ARV regime Positive Total 
   
Lam-Sta-Eff 1 1 
 100.00 100.00 
 7.69 7.69 
   
Lam-Efa-Sta 4 4 
 100.00 100.00 
 30.77 30.77 
   
Lam-Sta-Nev 1 1 
 100.00 100.00 
 7.69 7.69 
   
Lam-Efa-Aba 2 2 
 100.00 100.00 
 15.38 15.38 
   
Ten-Lam-L/R 2 2 
 100.00 100.00 
 15.38 15.38 
   
Ten-Lam-Efa 1 1 
 100.00 100.00 
 7.69 7.69 
   
L/R-Emt/Ten 1 1 
 100.00 100.00 
 7.69 7.69 
   
Aba-Lam-Efa 1 1 
 100.00 100.00 
 7.69 7.69 
   
Total 13 13 
 100.00 100.00 





. tab arv_regime hiv_status, exact 
 
 HIV status 
ARV regime Positive Total 
   
Lam-Sta-Eff 1 1 
Lam-Efa-Sta 4 4 
Lam-Sta-Nev 1 1 
Lam-Efa-Aba 2 2 
Ten-Lam-L/R 2 2 
Ten-Lam-Efa 1 1 
L/R-Emt/Ten 1 1 
Aba-Lam-Efa 1 1 
   
Total 13 13 
 
 









Year of Dx HIV status 
of HIV Positive Total
































   














. tab hivdx_date hiv_status, exact 
 
Year of Dx HIV status 
of HIV Positive Total






















 HIV status  
cytology Negative Positive Total
    
1 8 5 13
 61.54 38.46 100.00
 57.14 38.46 48.15
    
2 4 5 9
 44.44 55.56 100.00
 28.57 38.46 33.33
    
3 2 2 4
 50.00 50.00 100.00
 14.29 15.38 14.81
    
4 0 1 1
 0.00 100.00 100.00
 0.00 7.69 3.70
    





 51.85 48.15 100.00







. tab cytology hiv_status, exact 
 
Enumerating sample-space combinations: 
stage 4: enumerations = 1 
stage 3: enumerations = 2 
stage 2: enumerations = 2 
stage 1: enumerations = 0 
 
  HIV status   
cytology Negative Positive Total 
      
1 8 5 13 
2 4 5 9 
3 2 2 4 
4 0 1 1 
      
Total 14 13 27 
 Fisher's exact = 0.806
 









 HIV status  
histology Negative Positive Total
    
1 14 9 23
 60.87 39.13 100.00
 100.00 69.23 85.19
    
2 0 4 4
 0.00 100.00 100.00
 0.00 30.77 14.81
    
Total 14 13 27
 51.85 48.15 100.00
 100.00 100.00 100.00
 
 
. tab histology hiv_status, exact 
 
 HIV status  
histology Negative Positive Total
    
1 14 9 23
2 0 4 4
















. **I think the main questions are:  
. **1) does longer immunosuppression equal SIL?  
. **2) do the HIV patients have a bigger chance of having it?  
. **3) does having warts put you at risk?  
.  
.  
. univar tx_months, by (cytology) 
 




    --------------  --------------  
 




tx_months 13 52.45 25.33 8.98 34.36 62.27 73.02 84.03
------------------------------------------------------------------------------- 
 




    --------------  --------------  
 




tx_months 9 48.24 21.72 18.38 36.39 50.70 61.68 77.42
------------------------------------------------------------------------------- 
 




    --------------  --------------  
 




tx_months 4 43.51 21.32 21.53 25.40 43.82 61.63 64.87
------------------------------------------------------------------------------- 
 




    --------------  --------------  
 








. oneway tx_months cytology      
 Analysis of Variance    
Source SS df MS F Prob > F 
       
Between groups 1560.14303 3 520.047675 0.93 0.4412 
Within groups 12833.8182 23 557.992094    
       
Total 14393.9612 26 553.613892    
Bartlett's test for equal variances: chi2(2) =   0.2658  Prob>chi2 = 0.876 
 
note: Bartlett's test performed on cells with positive 


















 HIV status  
cytology Negative Positive Total
    
1 8 5 13
 61.54 38.46 100.00
 57.14 38.46 48.15
    
2 4 5 9
 44.44 55.56 100.00
 28.57 38.46 33.33
    
3 2 2 4
 50.00 50.00 100.00
 14.29 15.38 14.81
    
4 0 1 1
 0.00 100.00 100.00
 0.00 7.69 3.70
    
Total 14 13 27
 51.85 48.15 100.00
 100.00 100.00 100.00
 
 
. tab cytology hiv_status, exact 
 
Enumerating sample-space combinations: 
stage 4: enumerations = 1 
stage 3: enumerations = 2 
stage 2: enumerations = 2 
stage 1: enumerations = 0 
 
  HIV status   
cytology Negative Positive Total 
      
1 8 5 13 
2 4 5 9 
3 2 2 4 
4 0 1 1 
      
Total 14 13 27 
 Fisher's exact = 0.806
 

















 histology  
cytology 1 2 Total
    
1 12 1 13
 92.31 7.69 100.00
 52.17 25.00 48.15
    
2 8 1 9
 88.89 11.11 100.00
 34.78 25.00 33.33
    
3 3 1 4
 75.00 25.00 100.00
 13.04 25.00 14.81
    
4 0 1 1
 0.00 100.00 100.00
 0.00 25.00 3.70
    
Total 23 4 27
 85.19 14.81 100.00
 100.00 100.00 100.00
 
 
. tab cytology histology, exact 
 
Enumerating sample-space combinations: 
stage 4: enumerations = 1 
stage 3: enumerations = 2 
stage 2: enumerations = 4 
stage 1: enumerations = 0 
 
  histology    
cytology 1 2 Total 
      
1 12 1 13 
2 8 1 9 
3 3 1 4 
4 0 1 1 
      
Total 23 4 27 
 Fisher's exact =  0.179
 












Macroscopi      
c disease      
before  cytology   
stain 1 2 3 4 Total
      
None 10 6 4 1 21
 47.62 28.57 19.05 4.76 100.00
 76.92 66.67 100.00 100.00 77.78
      
Warts 1 2 0 0 3
 33.33 66.67 0.00 0.00 100.00
 7.69 22.22 0.00 0.00 11.11
      
Other 2 1 0 0 3
 66.67 33.33 0.00 0.00 100.00
 15.38 11.11 0.00 0.00 11.11
      
Total 13 9 4 1 27
 48.15 33.33 14.81 3.70 100.00
 100.00 100.00 100.00 100.00 100.00
 
 
. tab prestain cytology, exact 
 
Enumerating sample-space combinations: stage 4: 
enumerations = 1 
stage 3: enumerations = 1 stage 2: 
enumerations = 2 stage 1: enumerations = 
0 
 
Macroscopi      
c disease      
before  cytology    
stain 1 2 3 4 Total
       
None 10 6 4 1 21
Warts 1 2 0 0 3
Other 2 1 0 0 3
       
Total 13 9 4 1 27





end of do-file 
 
. 
 
